Latest advances on the maintenance therapy of multiple myeloma.
10.7534/j.issn.1009-2137.2015.01.047
- Author:
Yun ZHUANG
1
;
Qun SHEN
2
Author Information
1. Department of Hematoloy, Jiangsu Province Hospital of Traditional Chinese Medicine, The First Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
2. Department of Hematoloy, Jiangsu Province Hospital of Traditional Chinese Medicine, The First Clinical Medical College of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China. E-mail: shenq@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Boronic Acids;
Bortezomib;
Disease-Free Survival;
Hematopoietic Stem Cell Transplantation;
Humans;
Multiple Myeloma;
Pyrazines;
Thalidomide;
analogs & derivatives
- From:
Journal of Experimental Hematology
2015;23(1):250-254
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is an uncurable disease. Chemotherapy with standard dose or autologous stem cell transplantation (auto-HSCT) after chemotherapy with high dose is able to induce remission, but relapse still exists. For this reason the ultimate goal of MM treatment is to improve relapse free survival (RFS) and progression free survival (PFS) efficiently. Recently, maintenance therapy made substantial progress in improving progression-free survival and overall survival (OS) of patients with multiple myeloma, especially thalidomide, lenalidomide and bortezomib used in clinic. Here, the latest advances of clinical researches on maintenance therapy of MM are summarized briefly in this review.
